A stronger and safer United Kingdom through global health R&D investment
New research makes the investment case crystal clear: the UK's funding of neglected disease R&D saves lives, creates jobs and boosts the UK economy
Hubs
The Impact of Global Health R&D Hub
Is this the world's best investment? The success of global health R&D over the past 20 years is a resounding one - and yet R&D funding to tackle neglected diseases has fallen since the pandemic. In breakthrough work, we find a staggering return on that investment in terms of societal benefit.
Hub Editors
Vanessa Candeias
Strategy and External Affairs Lead
Andrew Tuttle
Chief Strategy Officer
making an impact
Global health is the world's best investment
In breakthrough work, we analyse the impact of global health R&D, showing the return on investment in health and economic terms for the first time. We look at the products which have been gamechangers over the last two decades and model the future returns of health innovations which transform the health and economic outlook for vulnerable populations.
PDF of the global reportInteractive report findings$405
returned in societal value for every $1 invested
30%
drop in deaths from poverty-related diseases in last 20 years
Spotlight on the United Kingdom
Ahead of the UK government's spending review, we release a deep dive into the investment case for the United Kingdom which shows the huge return on investing in R&D.
Read more
A stronger and safer United Kingdom through global health R&D investment: Foreword by Professor David Lalloo and Professor Liam Smeeth
The Vice-Chancellor of the Liverpool School of Tropical Medicine and the Director of the London School of Hygiene and Tropical Medicine reflect on Impact Global Health's research...
Neglected disease R&D: A smart investment for a safer, stronger United Kingdom
As we publish our report into the impact of the UK's funding of global health R&D, Dr Celine Aerts argues that cutting funding is a short-sighted decision.
investment case
Investing for a stronger and safer United Kingdom
A leader in research and development for neglected diseases, the United Kingdom sees a significant return on this investment economically, geopolitically and in terms of its own health security. Take a look.
All resources in this hub
40 min read
The 2025 Neglected Disease R&D Pipeline review: Time to close the gaps
Amid reduced funding, political uncertainty, and rising infectious disease, this report assesses the health of the neglected diseases (ND) pipeline to empower funders, policymakers, and advocates to prioritize high impact investments. This report delves into a decade of ND pipeline insights to guide future investment strategies.
10 min read
A stronger and safer United Kingdom through global health R&D investment: Foreword by Professor David Lalloo and Professor Liam Smeeth
The Vice-Chancellor of the Liverpool School of Tropical Medicine and the Director of the London School of Hygiene and Tropical Medicine reflect on Impact Global Health's research into the impact of UK investment in neglected disease R&D
40 min read
A stronger and safer United Kingdom through global health R&D investment
New research makes the investment case crystal clear: the UK's funding of neglected disease R&D saves lives, creates jobs and boosts the UK economy
10 min read
Neglected disease R&D: A smart investment for a safer, stronger United Kingdom
As we publish our report into the impact of the UK's funding of global health R&D, Dr Celine Aerts argues that cutting funding is a short-sighted decision.
5 min read
Investing for a stronger and safer United Kingdom: Video
Key messages from the April 2025 report on the UK's return on investing in neglected disease R&D
10 min read
The value of vaccines: what to do in the face of funding cuts which put decades of progress at risk
In this blog, Dr Nick Chapman urges us to prepare for a future that doesn’t look like the past
-404x303.webp)
10 min read
In turbulent times, Europe must double down on its investments in Global Health R&D
Vanessa Candeais shows how investment in global public goods, global solidarity, and equity is a strategic necessity for Europe, providing clarity and leadership for the world and for its own future.
45 min read
Global health R&D makes a strong investment case for Team Europe
Following on from our milestone report on the Impact of Global Health R&D, we launch a knowledge series looking at the investment case for specific regions. This report explores the impact of global health R&D funding from Team Europe.
15 min read
Universal Health Coverage: It’s on governments to ensure equity and access to lifesaving innovations
On Universal Health Coverage Day 2024, our Strategy & External Affairs Lead, Vanessa Candeias, explains why governments must take the lead in ensuring equitable access to the impending pipeline of health innovations.
You may also be interested in
Report Library
Browse our full archive of reports. Filter by health area, disease or condition, product, and date. Written by our expert analysts, our reports highlight key messages in the data, make the case for change and offer actionable recommendations.
Disease and condition
Our Health Areas resource gives you an at-a-glance summary of the state of innovation and annual R&D investment by disease and condition. Updated regularly, this is a unique quick reference for the global health community.